STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug
South Korea’s anti-trust regulator has fined AstraZeneca and a local generic drugmaker a total of $1.8 million for striking a deal that thwarted rivals from marketing a cancer treatment, the latest instance in which a global pharmaceutical company has been cited for anticompetitive behavior.
In this case, the local company, Alvogen, reportedly agreed to suspend plans to release a version of an AstraZeneca medication called Zoladex, which is used to combat prostate and breast cancer. In return, Alvogen gained exclusive rights to market generic versions of three other medicines made by AstraZeneca.
